Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Audrey Gibson

Physician Assistant, Medical Gainesville, GA Physician Assistant

NPI 1053346296 CMS profile 10440167

700 S Enota Dr Ne, Gainesville, GA 30501

Open in the dashboard

General payments

$301,776

1,231 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Audrey Gibson of Gainesville, GA is reported in the CMS Open Payments database as having received $301,776 across 1,231 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $113,142 311
2024 General $67,043 266
2023 General $73,216 248
2022 General $39,823 254
2021 General $8,552 152

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Audrey Gibson
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Audrey Gibson were reported at $113,142. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Audrey Gibson Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $8,552 $156 $41–$563 $132
2022 $39,823 $185 $55–$649 $149
2023 $73,216 $199 $58–$717 $160
2024 $67,043 $206 $62–$740 $164
2025 $113,142 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $137,092 564 payments
  2. Janssen Biotech, Inc. $75,556 141 payments
  3. Genzyme Corporation $22,608 61 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $18,382 60 payments
  5. Novartis Pharmaceuticals Corporation $18,123 114 payments
  6. Janssen Scientific Affairs, LLC $12,851 16 payments
  7. UCB, Inc. $6,974 79 payments
  8. AstraZeneca Pharmaceuticals LP $3,871 25 payments
  9. Lilly USA, LLC $1,682 7 payments
  10. Eli Lilly and Company $1,600 1 payment
  11. Other $3,036 163 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $171,115 110 payments
  2. Travel and Lodging $58,849 193 payments
  3. Consulting Fee $46,383 26 payments
  4. Food and Beverage $25,293 898 payments
  5. Education $137 4 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $76,077 401 payments
  2. SIMPONI ARIA $66,851 99 payments
  3. TREMFYA $64,746 122 payments
  4. SKYRIZI Immunology $29,982 68 payments
  5. KEVZARA $22,610 58 payments
  6. SKYRIZI Immunology $20,220 85 payments
  7. OFEV $13,023 28 payments
  8. COSENTYX $11,575 79 payments
  9. Bimzelx $6,067 28 payments
  10. STELARA $5,656 11 payments
  11. Other $13,357 367 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

165

Median for Physician Assistant: 241

Drug cost

$170,009

Median for Physician Assistant: $4,110

Branded share of claims

33.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 13 $86,455
Enbrel Sureclick Etanercept Brand 11 $80,662
Hydroxychloroquine Sulfate Generic 29 $1,649
Methotrexate Methotrexate Sodium Brand 31 $531
Prednisone Generic 55 $511
Diclofenac Sodium Generic 14 $130
Tramadol Hcl Generic 12 $71

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$46,132

Of which drugs: $816

Medicare patients

230

Average age 74

Services billed

2,252

181 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 35%
Ischemic heart disease 33%
Chronic kidney disease 33%
Diabetes 27%
Depression 25%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$18,030 — —
OFEV
$11,618 — —
KEVZARA
$11,452 — —
TREMFYA
$9,398 — —
SIMPONI ARIA
$9,067 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

1,231 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record